title: [Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy].
abstract: Non-Hodgkin lymphomas (NHL) comprise a heterogeneous collection of lymphoproliferative malignancies. Follicular lymphoma (FL) is the second most common NHL sub-type. Over the last years, the introduction of the anti-CD20 monoclonal antibody rituximab has radically changed treatment of FL. After several large prospective randomized trials demonstrated prolongation of remission, current European indications for rituximab include the first-line treatment of patients with stage III-IV FL in combination with polychemotherapy such as CVP or CHOP. This paper discusses the treatment of primary nodal FL with secondary cutaneous involvement with rituximab as monotherapy without additional chemotherapy.
authors.affiliation: Eduard-Arning-Klinik für Dermatologie und Allergologie, Asklepios Klinik St.Georg, Lohmühlenstr. 5, 20099, Hamburg. ri.koch@asklepios.com
authors.forename: R
authors.initials: R
authors.lastname: Koch
authors.forename: C A
authors.initials: CA
authors.lastname: Sander
mesh_terms: D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D000069283:Rituximab; D012871:Skin Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab